Opportunity Information: Apply for RFA EB 12 001
Apply for RFA EB 12 001
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Development and Translation of Medical Technologies to Reduce Health Disparities (R43/R44)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.286 Discovery and Applied Research for Technological Innovations to Improve Human Health 93.307 Minority Health and Health Disparities Research 93.846 Arthritis, Musculoskeletal and Skin Diseases Research.
- This funding opportunity was created on Mar 9, 2012 and posted on Mar 9, 2012.
- Applicants must submit their applications by Jan 7, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $2,200,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: Small businesses.
- Other Eligible Applicants include the following Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity. A small business concern is one that, at the time of award of Phase I and Phase II, meets all of the following criteria Is organized for profit, with a place of business located in the United States, which operates primarily within the United States or which makes a significant contribution to the United States economy through payment of taxes or use of American products, materials or labor Is in the legal form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust or cooperative, except that where the form is a joint venture, there can be no more than 49 percent participation by foreign business entities in the joint venture Is at least 51 percent owned and controlled by one or more individuals who are citizens of, or permanent resident aliens in, the United States, or it must be a for profit business concern that is at least 51 percent owned and controlled by another for profit business concern that is at least 51 percent owned and controlled by one or more individuals who are citizens of, or permanent resident aliens in, the United States, except in the case of a joint venture, where each entity to the venture must be 51 percent owned and controlled by one or more individuals who are citizens of, or permanent resident aliens in, the United States and Has, including its affiliates, not more than 500 employees. SBCs must also meet the other regulatory requirements found in 13 C.F.R. Part 121. Business concerns, other than investment companies licensed, or state development companies qualifying under the Small Business Investment Act of 1958, 15 U.S.C. 661, et seq., are affiliates of one another when either directly or indirectly, (a) one concern controls or has the power to control the other or (b) a third party/parties controls or has the power to control both. Business concerns include, but are not limited to, any individual (sole proprietorship) partnership, corporation, joint venture, association, or cooperative. The SF424 (R and R) SBIR/STTR Application Guide should be referenced for detailed eligibility information.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Development and Translation of Medical Technologies to Reduce Health Disparities (R43/R44) funding opportunity (RFA-EB-12-001) was a National Institutes of Health (NIH) Small Business Innovation Research (SBIR) solicitation designed to help U.S. small businesses move practical medical technologies toward real-world use in communities that experience health disparities. The central goal was not just invention for invention's sake, but the development and translation of tools that measurably reduce gaps in health care access and health outcomes across underserved or disparity-affected populations. In other words, the program aimed to support small companies in building technologies that can actually work in the settings where disparities occur, and that can be adopted and sustained there.
A key emphasis of the FOA was that the proposed medical technologies needed to be appropriate for disparity populations in several concrete ways. NIH highlighted that responsive technologies should be effective (able to deliver meaningful clinical or health impact), affordable (realistic for low-resource clinics and patients, and supportive of broad access), culturally acceptable (designed with the population's needs, preferences, language, trust concerns, and care practices in mind), and deliverable to those who need them (usable in the real environments where people receive care, including settings with limited infrastructure, staffing, or specialty services). That framing signals that proposals were expected to think beyond a prototype and address practical barriers to uptake such as usability, workflow fit, cost constraints, and implementation in community-based or safety-net systems.
The solicitation used the SBIR R43/R44 mechanism, which corresponds to the standard two-phase SBIR structure. Phase I (R43) generally supports early feasibility and proof-of-concept work, while Phase II (R44) supports more advanced research and development aimed at bringing the technology closer to commercialization or deployment. What made this opportunity distinctive is that it required collaboration to be built in from the start: to be considered responsive, an application had to include a formal collaboration with a health care provider or another health care organization that serves a health disparity population, and that collaboration needed to be active in both Phase I and Phase II. This requirement reflects NIH's intent to ensure that projects are guided by on-the-ground clinical realities and community needs, rather than being developed in isolation from the people and systems that would ultimately use the technology.
Eligibility was limited to U.S. small business concerns as defined by SBIR rules and federal small business regulations. The FOA specified that an eligible small business had to be organized for profit, have a place of business in the United States and operate primarily in the United States (or otherwise make a significant contribution to the U.S. economy through taxes or the use of American products, materials, or labor), and be in an allowable legal form such as a sole proprietorship, partnership, LLC, corporation, association, trust, cooperative, or qualifying joint venture. The company also had to be at least 51 percent owned and controlled by U.S. citizens or permanent resident aliens (with additional ownership conditions applying to joint ventures), and could not exceed 500 employees including affiliates. The FOA also pointed applicants to the SF424 (R&R) SBIR/STTR Application Guide and to 13 C.F.R. Part 121 for the detailed regulatory framework, including how affiliation is determined (for example, through direct or indirect control by another entity or shared control by a third party).
From an administrative and funding standpoint, this was a discretionary grant opportunity categorized under the health activity area. It listed CFDA numbers 93.286 (Discovery and Applied Research for Technological Innovations to Improve Human Health), 93.307 (Minority Health and Health Disparities Research), and 93.846 (Arthritis, Musculoskeletal and Skin Diseases Research), which signals that the scope could span multiple disease areas and technology domains as long as the core purpose remained reducing disparities through medical technology development and translation. The FOA stated there was no cost-sharing or matching requirement. NIH estimated total funding of $2,200,000 for the opportunity, and it listed an award ceiling of $200,000. The opportunity was posted and created on March 9, 2012, with an original (and current) closing date of January 7, 2013, and an archive date of February 7, 2013, meaning it is no longer open but remains available as a reference point for how NIH framed this topic and its expectations at the time.
For applicants or interested parties seeking the full official text, NIH provided an additional information link to the full announcement page. The contact pathway in the provided source data routed technical access or linking problems to the NIH Office of Extramural Research (OER) Webmaster (FBOWebmaster@OD.NIH.GOV), which is typical for issues related to accessing the FOA online rather than scientific or programmatic questions about fit.
Frequently Asked Questions (FAQ)
What is the purpose of this funding opportunity?
The Development and Translation of Medical Technologies to Reduce Health Disparities (R43/R44) opportunity (RFA-EB-12-001) was an NIH Small Business Innovation Research (SBIR) solicitation intended to help U.S. small businesses develop and translate practical medical technologies into real-world use in communities experiencing health disparities. The emphasis was on technologies that can measurably reduce gaps in health care access and health outcomes in underserved or disparity-affected populations.
What types of projects were considered responsive?
Projects were expected to go beyond invention alone and address real-world adoption. NIH emphasized that responsive medical technologies should be effective (deliver meaningful clinical or health impact), affordable (realistic for low-resource clinics and patients and supportive of broad access), culturally acceptable (aligned with the population's needs, preferences, language, trust concerns, and care practices), and deliverable (usable in the environments where people receive care, including settings with limited infrastructure, staffing, or specialty services).
What does "development and translation" mean in this context?
In this opportunity, "development and translation" meant moving practical medical technologies toward deployment and use in the communities where disparities occur. That framing implied attention to barriers like usability, workflow fit, cost constraints, and implementation in community-based or safety-net systems, not just producing a prototype.
Which grant mechanisms were used?
The solicitation used the SBIR R43/R44 mechanism, which follows the standard two-phase SBIR structure: Phase I (R43) generally supports early feasibility and proof-of-concept work, and Phase II (R44) supports more advanced research and development intended to bring the technology closer to commercialization or deployment.
Was collaboration required?
Yes. To be considered responsive, an application had to include a formal collaboration with a health care provider or another health care organization that serves a health disparity population, and that collaboration needed to be active in both Phase I and Phase II.
Who was eligible to apply?
Eligibility was limited to U.S. small business concerns as defined by SBIR rules and federal small business regulations. The FOA indicated that applicants should follow the SF424 (R&R) SBIR/STTR Application Guide and referenced 13 C.F.R. Part 121 for detailed requirements (including rules about affiliation).
What business structure requirements applied to eligible small businesses?
The eligible small business had to be organized for profit, have a place of business in the United States, and operate primarily in the United States (or otherwise make a significant contribution to the U.S. economy through taxes or the use of American products, materials, or labor). Allowable legal forms included a sole proprietorship, partnership, LLC, corporation, association, trust, cooperative, or qualifying joint venture.
What ownership and control requirements applied?
The company had to be at least 51 percent owned and controlled by U.S. citizens or permanent resident aliens. The FOA also noted that additional ownership conditions can apply to joint ventures.
Was there a company size limit?
Yes. The small business could not exceed 500 employees, including affiliates.
What does "affiliates" mean in determining size eligibility?
The FOA pointed to 13 C.F.R. Part 121 for the regulatory framework, including how affiliation is determined (for example, through direct or indirect control by another entity or shared control by a third party). Employee counts included affiliates under those rules.
What was the activity area for this opportunity?
It was categorized as a discretionary grant opportunity under the health activity area.
Which CFDA numbers were associated with the opportunity?
The opportunity listed CFDA numbers 93.286 (Discovery and Applied Research for Technological Innovations to Improve Human Health), 93.307 (Minority Health and Health Disparities Research), and 93.846 (Arthritis, Musculoskeletal and Skin Diseases Research). This suggested the scope could span multiple disease areas and technology domains as long as the core purpose remained reducing disparities through medical technology development and translation.
Was cost sharing or matching required?
No. The FOA stated there was no cost-sharing or matching requirement.
How much funding was NIH expecting to make available?
NIH estimated total funding of $2,200,000 for the opportunity.
What was the award ceiling?
The opportunity listed an award ceiling of $200,000.
When was the opportunity posted and when did it close?
The opportunity was posted and created on March 9, 2012. The original (and current) closing date was January 7, 2013, and the archive date was February 7, 2013.
Is this funding opportunity still open?
No. Based on the listed closing date (January 7, 2013) and archive date (February 7, 2013), it is no longer open and remains available as a reference for how NIH framed this topic and its expectations at the time.
Where could someone find the official full text of the announcement?
NIH provided an additional information link to the full announcement page for the official text.
Who should be contacted for technical problems accessing the FOA online?
The contact pathway in the provided source data routed technical access or linking problems to the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
Is the listed contact intended for scientific or programmatic questions?
The provided contact was described as typical for issues related to accessing the FOA online (technical access or linking problems) rather than scientific or programmatic questions about fit.
Browse more opportunities from the same category: Health
Next opportunity: Novel Presentation of Health Related Data
Previous opportunity: University Centers for Excellence in Developmental Disabilities Education, Research, and Service (UCEDD)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA EB 12 001
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA EB 12 001) also looked into and applied for these:
| Funding Opportunity |
|---|
| Strengthening Blood Donor Associations in Mozambique under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH12 1223 Funding Number: CDC RFA GH12 1223 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $100,000 |
| Public Health Conference Support for Birth Defects and Developmental Disabilities Apply for CDC RFA DD12 1203 Funding Number: CDC RFA DD12 1203 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $100,000 |
| Building the capacity of the National AIDS Control Program of the Ministry of Health to Expand Coordinated HIV Prevention, Care, Treatment, and Strategic Information Programs in the United Republic of Tanzania under the Presidents Emergency Plan for Apply for CDC RFA GH12 1240 Funding Number: CDC RFA GH12 1240 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $5,000,000 |
| Partnerships for Interventions to Treat Chronic, Persistent and Latent Infections (R21/R33) Apply for RFA AI 12 020 Funding Number: RFA AI 12 020 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| NIDCR Small Research Grants for Oral Health Data Analysis and Statistical Methodology Development (R03) Apply for PAR 12 120 Funding Number: PAR 12 120 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Child Survival Health Grants Program Fiscal Year 2012 Apply for RFA OAA 12 000008 Funding Number: RFA OAA 12 000008 Agency: Agency for International Development Category: Health Funding Amount: $13,500,000 |
| Initiative to Reduce Avoidable Hospitalizations among Nursing Facility Residents Apply for CMS 1E1 12 002 Funding Number: CMS 1E1 12 002 Agency: Centers for Medicare Medicaid Services Category: Health Funding Amount: $30,000,000 |
| Studies in Parkinsons Disease Biomarkers Discovery (U01) Apply for RFA NS 12 011 Funding Number: RFA NS 12 011 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Exploratory Laboratory and Analysis Projects in Parkinsons Disease Biomarkers (U18) Apply for RFA NS 12 010 Funding Number: RFA NS 12 010 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| NIDCD Phase I/II/III Clinical Trials in Communication Disorders (U01) Apply for PAR 12 123 Funding Number: PAR 12 123 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCD Planning Grant for Phase III Clinical Trials in Communication Disorders (U34) Apply for PAR 12 124 Funding Number: PAR 12 124 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Supporting Improved Health for all People in the Kingdom of Cambodia by Strengthening the Ministry of Healths Capacity to Lead Disease Prevention and Control Efforts and Develop Sustainable Health Delivery Systems under the Presidents Emergency Plan Apply for CDC RFA GH12 1226 Funding Number: CDC RFA GH12 1226 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $700,000 |
| State Public Health Coordinating Center for Autism Apply for HRSA 12 131 Funding Number: HRSA 12 131 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Primary Care Training and Enhancement Interdisciplinary and Interprofessional Joint Graduate Degree Program Apply for HRSA 12 025 Funding Number: HRSA 12 025 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Immunization Information Systems (IIS) Capacity Building Apply for CDC RFA IP12 1201 Funding Number: CDC RFA IP12 1201 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $520,000 |
| Strengthening Local Ownership for the Sustainable Provision of HIV/AIDS Services in the Health Bureaus of Southern Nations, Nationalities and Peoples (SNNP) Regional State and Addis Ababa City Administration of the Federal Democratic Republic of Ethi Apply for CDC RFA GH12 1222 Funding Number: CDC RFA GH12 1222 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $500,000 |
| Use Oriented Basic Research Change Mechanisms of Behavioral Social Interventions (Admin Supp) Apply for PA 12 119 Funding Number: PA 12 119 Agency: National Institutes of Health Category: Health Funding Amount: $75,000 |
| Construction of a Regional Reference Laboratory in Leribe Apply for CDC RFA GH12 1252 Funding Number: CDC RFA GH12 1252 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
| Caribbean Regional Epidemiology and Laboratory Training Program (RELTP) under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH12 1206 Funding Number: CDC RFA GH12 1206 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,300,000 |
| Offender Reentry Program Apply for TI 12 003 Funding Number: TI 12 003 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $400,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA EB 12 001", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.